publication . Article . 2014

Prevalencia de bacterias Gram negativas portadoras del gen blaKPC en hospitales de Colombia

Robinson Pacheco; Lyda Osorio; Correa, Adriana M.; María Virginia Villegas;
Open Access Spanish; Castilian
  • Published: 01 Apr 2014
  • Publisher: BIOMÉDICA
Abstract
Introducción. Las enzimas carbapenemasas de tipo KPC tienen gran capacidad de diseminación, son causantes de epidemias y se asocian a mayor mortalidad y estancia hospitalaria. En Colombia se han venido reportando cada vez más desde 2007, pero se desconoce la prevalencia hospitalaria. Objetivo. Estimar la prevalencia hospitalaria del gen bla KPC . Materiales y métodos. Se evaluó la presencia del gen bla KPC y su 'clonalidad' en aislamientos de enterobacterias y Pseudomonas aeruginosa de pacientes hospitalizados. Resultados. De los 424 aislamientos evaluados durante el periodo de estudio, 273 cumplieron con criterios de elegibilidad, 31,1 % fue positivo para el ge...
Subjects
Medical Subject Headings: bacterial infections and mycosesbiochemical phenomena, metabolism, and nutritionpolycyclic compounds
free text keywords: bacterias Gram negativas, prevalencia, farmacorresistencia bacteriana, infección hospitalaria, Colombia., Colombia, Gram-negative bacteria, prevalence, drug resistance, bacterial, cross infection, General Biochemistry, Genetics and Molecular Biology, General Medicine, Gram-negative bacterial infections, Gram, Medicine, business.industry, business, Bacterial protein, Molecular biology, Virology, Gram-negative bacteria, prevalence, cross infection, Colombia., R, Arctic medicine. Tropical medicine, RC955-962
28 references, page 1 of 2

1. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemaseproducing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist. 2006;12:223-30. http://dx.doi.org/10.1089/mdr. 2006.12.223

2. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med. 2003;24:121-34. http://dx.doi.org/1010.1055/s2003-37923

3. Walsh TR. Clinically significant carbapenemases: An update. Curr Opin Infect Dis. 2008;21:367-71. http://dx.doi. org/10.1097/QCO.0b013e328303670b

4. Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-betalactamase among Gram-negative bacilli in Latin America2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis. 2011;15:34-9. http://dx.doi.org/10.1590/S1413-86702011000100007

5. Briceño DF, Correa A, Valencia C, Torres JA, Pacheco R, Montealegre MC, et al. Actualización de la resistencia a los antimicrobianos de bacilos Gram negativos aislados en hospitales nivel III de Colombia, años 2006, 2007 y 2008. Biomedica. 2010;30:371-81.

6. Tafur JD, Torres JA, VIllegas MV. Mecanismos de resistencia a los antibióticos en bacterias Gram negativas. Infectio. 2008;12:217-26.

7. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54: 969-76. http://dx.doi.org/10.1128/AAC.01009-09

8. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, et al. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis. 2010;16:1349-56. http://dx.doi.org/10. 3201/eid1609.091389

9. Suárez CJ, Kattan JN, Guzmán AM, VIllegas MV. Mecanismos de resistencia a carbapenems en P. aeruginosa, Acinetobacter y Enterobacteriaceae y estrategias para su prevención y control. Infectio. 2006;10:85-93. [OpenAIRE]

10. Maya JJ, Ruiz SJ, Blanco VM, Gotuzzo E, Guzmán-Blanco M, Labarca J, et al. Currents status of carbapenemases in Latin America. Expert Rev Anti Infect Ther. 2013;11:657-67. http://dx.doi.org/10.1586/14787210.2013.811924

11. Gootz TD, Lescoe MK, Dib-Hajj F, Dougherty BA, He W, Della-Latta P, et al. Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. Antimicrob Agents Chemother. 2009;53:1998- 2004. http://dx.doi.org/10.1128/AAC.01355-08 [OpenAIRE]

12. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. Antimicrob Agents Chemother. 2008;52:1257-63. http://dx.doi.org/10.1128/AAC. 01451-07

13. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, NavonVenezia S, Carmeli Y, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother. 2009;53:3365-70. http://dx.doi.org/10.1128/AAC.00126-09

14. Villegas MV, Lolans K, Correa A, Suárez CJ, López JA, Vallejo M, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50:2880-2. http://dx.doi.org/1010. 1128/AAC.00186-06

15. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs. 2002;3:218-24.

28 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue